NPC - AXEL Study : Axitinib-Avelumab

NCT04562441 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic NPC

Interventions

DRUG: Axitinib
DRUG: Avelumab

Sponsor

Chinese University of Hong Kong